Prostate Cancer

In this Q&A, Shiv B. Patel, MD, reflects on how prostate cancer screening has evolved from a one-size-fits-all approach to a more individualized strategy.

The target enrollment goal has been reached in the phase 3 BiPASS study, evaluating PSMA-PET plus MRI for prostate cancer detection.

Routine cardiovascular specialist referral improved cholesterol control in patients with prostate cancer but did not reduce cardiovascular events.

Closing racial disparities in prostate cancer requires meeting men in barbershops, churches, and community screenings—not just clinics, according to Justin Cohen, MD.

In this Q&A, Zachary Feuer, MD, discusses the implementation of a telehealth-based rapid access program for evaluating men with an elevated PSA.

The FDA has granted clearance to a phase 1 trial of ADI-212, a PSMA-targeted, gene-edited, armored cell therapy candidate under development for mCRPC.

A TRUMPET registry analysis found that initial disease presentation and family history were associated with survival outcomes in metastatic castration-resistant prostate cancer.

A national cohort study found that metabolic syndrome and its components were frequently documented within the first year of concurrent ADT and ARPI therapy for prostate cancer.

Clinicians across four cities weigh ARASEC and ARANOTE trial data, drug interactions, and access barriers in mCSPC treatment decisions.

The phase 2 MODeFIRe-1 trial will evaluate investigational MRT-2359 plus apalutamide in AR-mutated metastatic castration-resistant prostate cancer.

The phase 3 NRG-GU005 trial found SBRT improved bowel quality of life vs MH-IMRT but did not improve urinary outcomes or disease-free survival.

A recent study found active surveillance use for low-risk prostate cancer rose from 27% to 93% among veterans from 2005 to 2024.

A national analysis found that 51% of focal therapy procedures for prostate cancer occurred in patients with low-, high-, or very-high-risk disease, outside current guideline-supported settings.

The DIRECT-AI registry has enrolled its first patient to prospectively assess how the ArteraAI Prostate Test influences treatment decisions and outcomes in routine care.

An analysis of NHANES data found that higher intake of ultra-processed foods was associated with increased prostate cancer risk among US men.

A real-world analysis found that achieving a PSA level below 0.2 ng/mL was associated with improved overall survival in mCSPC.

These FAQs highlight key recommendations and practical takeaways from the 2026 AUA/ASTRO Clinically Localized Prostate Cancer guideline amendment.

The phase 3 PSMAddition trial found that adding lutetium Lu 177 vipivotide tetraxetan to ADT and an ARPI significantly improved rPFS in mHSPC.

A recap of the FDA submissions and regulatory decisions in urology from July 2026.

Four Urology Times Clinical Forums show that ARPI safety, drug interactions, and cognitive effects, not efficacy alone, guide mCSPC therapy selection.

The approval is supported by data from the phase 3 PSMAddition trial.

A 10-year registry analysis found focal HIFU and cryotherapy achieved durable cancer control and low prostate cancer mortality in localized disease.

This FAQ outlines the major recommendations from PCWG4 for urologists and clinical investigators involved in prostate cancer clinical trials.

CAPTAIN trial data showed TULSA preserved penile length, continence, and erectile function compared with robotic prostatectomy in localized prostate cancer.

The PDUFA target action date is in the fourth quarter of 2026.